Skinvisible, Inc.

As of March 31, 2026, Skinvisible, Inc. carries a market capitalization of 1.28M, placing it among publicly traded companies globally. Its enterprise value stands at 7.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Skinvisible, Inc. has 5.40M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 64.07, and the price-to-book ratio stands at -0.12.

These figures are as of March 31, 2026. The EV/Sales ratio of 353.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.08M versus a market cap of 1.28M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Skinvisible, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -55.04, indicating conservative leverage, while an interest coverage ratio of -0.81 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -780.91, reflecting losses generated across the asset base. The company generates approximately 10,000.00 in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Skinvisible, Inc.'s stock has declined approximately 60.98% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.37.

Over the twelve months ended March 31, 2026, Skinvisible, Inc. generated 20,000.00 in revenue and converted that into -1.05M in net income, yielding earnings per share of -0.19. EBITDA reached -462,095.00, while operating income came in at -482,401.00.

As of March 31, 2026, Skinvisible, Inc. holds 1,798.00 in cash and equivalents against 5.80M in total debt, resulting in a net debt position of 5.79M. Total book value stands at -10.53M, with working capital of -5.25M providing operational flexibility.

Skinvisible, Inc. produced -7,512.00 in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4,086.00 in capital expenditures, free cash flow totaled -11,598.00 - equivalent to 0.00 per share.

Over the twelve months ended March 31, 2026, Skinvisible, Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,412.00 and net profit margin of -5,251.06 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -0.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Skinvisible, Inc. shareholders.

Skinvisible, Inc.'s most recent stock split took place on January 4, 2019 with a 50:1 split ratio.

As of March 31, 2026, Skinvisible, Inc. has an Altman Z-Score of -2,692.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.